This study is looking at the safety of a special test system called the Loargys Arginine Test System. This system is used for people who are already being treated with Loargys for Arginase 1 deficiency (ARG1-D). ARG1-D is a rare condition where your body can't properly break down a substance called arginine, which can cause serious health problems. Loargys is a treatment that helps lower arginine levels. Because Loargys keeps breaking down arginine even after a blood sample is taken, this test system uses a special substance to make sure blood test results are accurate. The main goal of this study is to see how many side effects (adverse events) are related to using the Loargys Arginine Test System. You can join if you are receiving commercial Loargys for ARG1-D and are willing to sign a consent form.

Study design

This study is designed to enroll 100 participants. It is an interventional study, meaning participants will receive a specific intervention.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for side effects related to the Loargys Arginine Test System through study completion, up to 21 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.